Zadrozna-Sliwka Beata, Bolanowski Marek, Jawiarczyk Aleksandra, Kaluzny Marcin, Syrycka Joanna
Department of Endocrinology, Diabetology and Isotope Therapy, Medical University Wrocław, Poland.
Neuro Endocrinol Lett. 2008 Feb;29(1):178-84.
Hyperprolactinemia could be one of possible causes of bone loss. The reason is thought to be connected with hypogonadism due to PRL excess and the role of other hormones like PTH and PTH-rP. There is no data on the influence of PTH fractions (CAP and CIP) on bone turnover and density in hyperprolactinemia. The aim of the study was to assess the influence of PTH and its fractions on bone metabolism in hyperprolactinemia of various origin.
The study was carried out in 75 women. Group I consisted of 32 women with prolactinoma, group II consisted of 43 women with functional hyperprolactinemia. Both groups were subdivided in patients with hypogonadism and normal gonadal function. The control group consisted of 29 healthy women. In all subjects PRL, PTH and its fractions (CAP, CIP), and bone turnover markers (BAP, ICTP) were studied. BMD measurement was carried out using DXA.
In patients with functional hyperprolactinemia i-PTH and CAP levels were lower than in controls. CIP concentrations were lower in patients than in controls. CAP/CIP ratio was higher in patients with prolactinoma than in patients with functional hyperprolactinemia and controls. Higher values of bone turnover markers (BAP, ICTP) in patients groups and subgroups were shown as compared to controls. Some correlations between PTH and its fractions, and BMD and bone turnover were observed.
There is no direct benefit from the assessment of parathormone fractions and CAP/CIP ratio in the prognosis of bone metabolism changes in hyperprolactinemia of various origin.
高催乳素血症可能是骨质流失的潜在原因之一。其原因被认为与催乳素过多导致的性腺功能减退以及甲状旁腺激素（PTH）和甲状旁腺激素相关蛋白（PTH-rP）等其他激素的作用有关。目前尚无关于PTH组分（CAP和CIP）对高催乳素血症患者骨转换和骨密度影响的数据。本研究旨在评估PTH及其组分对不同病因高催乳素血症患者骨代谢的影响。
本研究纳入75名女性。第一组由32名催乳素瘤女性组成，第二组由43名功能性高催乳素血症女性组成。两组又根据性腺功能减退和性腺功能正常进一步细分。对照组由29名健康女性组成。对所有受试者检测催乳素（PRL）、甲状旁腺激素（PTH）及其组分（CAP、CIP）以及骨转换标志物（骨碱性磷酸酶（BAP）、Ⅰ型胶原交联C-末端肽（ICTP））。采用双能X线吸收法（DXA）测量骨密度。
功能性高催乳素血症患者的i-PTH和CAP水平低于对照组。患者的CIP浓度低于对照组。催乳素瘤患者的CAP/CIP比值高于功能性高催乳素血症患者和对照组。与对照组相比，患者组及其亚组的骨转换标志物（BAP、ICTP）值更高。观察到PTH及其组分与骨密度和骨转换之间存在一些相关性。
评估甲状旁腺激素组分和CAP/CIP比值对不同病因高催乳素血症患者骨代谢变化的预后并无直接益处。
